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Clinical Outcomes of Molecular Tumor
Boards: A Systematic Review
Kara L. Larson, PhD1; Bin Huang, PhD1,2; Heidi L. Weiss, PhD1; Pam Hull, PhD1; Philip M. Westgate, PhD3; Rachel W. Miller, MD1,4;
Susanne M. Arnold, MD1,5; and Jill M. Kolesar, PharmD1,6
abstract
PURPOSE We conducted this systematic review to evaluate the clinical outcomes associated with molecular
tumor board (MTB) review in patients with cancer.
METHODS A systematic search of PubMed was performed to identify studies reporting clinical outcomes in
patients with cancer who were reviewed by an MTB. To be included, studies had to report clinical outcomes,
including clinical benefit, response, progression-free survival, or overall survival. Two reviewers independently
selected studies and assessed quality with the Quality Assessment Tool for Before-After (Pre-Post) Studies with
No Control Group or the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies
depending on the type of study being reviewed.
RESULTS Fourteen studies were included with a total of 3,328 patients with cancer. All studies included patients
without standard-of-care treatment options andusually withmultiple prior lines of therapy. In studies reporting response
rates, patients receiving MTB-recommended therapy had overall response rates ranging from 0% to 67%. In the only
trial powered on clinical outcome and including a control group, the group receiving MTB-recommended therapy had
significantly improved rate of progression-free survival compared with those receiving conventional therapy.
CONCLUSION Although data quality is limited by a lack of prospective randomized controlled trials, MTBs appear
to improve clinical outcomes for patients with cancer. Future research should concentrate on prospective trials
and standardization of approach and outcomes.
JCO Precis Oncol 5:1122-1132. © 2021 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
INTRODUCTION
Precision medicine, specifically testing tumor tissue
for mutations with next-generation sequencing (NGS)
and using these results to guide therapy, is a major
advance in the treatment of cancer and is considered
standard of care (SOC) for many cancer types, in-
cluding lung cancer. Receiving a targeted therapy
yields substantial benefit for patients, since random-
ized, controlled trials have demonstrated that they are
more effective, less toxic, and improve quality of life
compared with cytotoxic cancer treatments.1
Despite the availability of clinical and affordable NGS,
targeted therapies, and insurance coverage, the use of
precision medicine remains low often because of in-
sufficient support to guide clinicians in interpreting and
acting on NGS results.2-4 As a response, many medical
centers have instituted molecular tumor boards (MTBs)
as a means to educate, interpret, and facilitate the use
of precision medicine for oncology patients.5 Most
MTBs consist of a multidisciplinary team of medical
oncologists, surgeons, genetic counselors, pharmacists,
pathologists, radiologists, and basic scientists.6 This
broad range of expertise allows for accurate and up-to-
date confirmation of diagnoses and identification of
actionable mutations and associated drugs, along with
the ability to pair patients with open clinical trials. It can
additionally identify potential germline mutations that
would require further genetic testing and counseling for
patients and their family members.
Many institutions have published descriptions of their
MTBs outlining their aims, patient populations, and
types of actionablemutations; however, data supporting
the clinical utility of MTBs are lacking.7-9 Therefore, we
focus on reports that also include clinical outcomes
such as clinical benefit (CB), response, and/or
progression-free survival (PFS). The purpose of this
systematic review is to evaluate the effect of MTBs on
clinical outcomes in patients with cancer.
METHODS
This review was performed following Preferred
Reporting Items for Systematic Reviews and Meta-
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Search Strategy and Inclusion and Exclusion Criteria
APubMed searchwas conducted onApril 1, 2020, using the
following query: molecular tumor board [All Fields]. Further
publications were found through additional means including
a bibliography screen of all selected articles. Articles were
excluded if they were not in English, were reviews, described
MTBs for pediatric patients, or did not contain data about CB
or survival. All remaining articles were screened for rele-
vancy, and any duplicates were removed.
Data Analysis
Data extraction was performed by two researchers (K.L.L.
and J.M.K.) for all publications examined. Any disagree-
ment was discussed between the researchers, and a
conclusion was reached. Because of data diversity and
differences in study setup, a meta-analysis was not per-
formed, and instead, data will be discussed using a de-
scription of the findings.
Calculations
The frequency of cases reviewed by each molecular tumor
board (MTB) was calculated using the following formula:
number of patients reviewed/

number of patients referred)
× 100.
The frequency of actionable mutations was calculated using
the following formula:
number of patients with an actionablemutation/

total number of patients reviewed by theMTB) × 100.
The frequency of patients who received MTB-directed tar-
geted therapy was calculated using the following formula:
number of patients that receivedMTB-directed therapy/

number of patientswith actionablemutations) × 100.
Outcomes were reported by the authors. For all cross-
sectional cohort studies, CB, if not explicitly provided,
was calculated by adding the number of patients who
achieved stable disease, partial response, or complete
response (CR). Overall response rate (ORR), if not explicitly
provided, was calculated by summing the number of pa-
tients who achieved partial response or CR. To calculate
rates regarding outcomes, the following formula was used:
number of patients with CB or ORR/

number of patients receivingMTB-directed therapy) × 100.
Finally, the outcomes if the trial employed and intention-to-
treat design were calculated using the following formula:
number of patients with CB or ORR, respectively/

total number of patients referred to theMTB) × 100.
Quality Assessment and Bias Determination
Quality assessment of the reviewed articles was performed
using either the Quality Assessment Tool for Before-After
(Pre-Post) Studies with No Control Group or the Quality
Assessment Tool for Observational Cohort and Cross-
Sectional Studies depending on the type of study being
reviewed.11 Each of the above tools were created and
validated by the National Institutes of Health and were
developed to determine the concepts that are necessary for
critical review. Responses were yes, not reported (NR), or
not applicable. Two researchers (K.L.L. and J.M.K.) per-
formed the assessments independently, and any dis-
agreements were discussed and resolved.
Additionally, the same researchers (K.L.L. and J.M.K.)
reviewed the studies for risk using the tool To Assess the
Risk of Bias in Cohort Studies validated by the Cochrane
Institute.12 Each study was rated as definitely yes, probably
yes, probably no, and definitely no with the risk of bias
increasing from yes to no.
RESULTS
A total of 71 articles were retrieved through a PubMed
search. Titles and abstracts of 31 studies were reviewed for
inclusion criteria. Ten articles were selected for a full
CONTEXT
Key Objective
What is the impact of a molecular tumor board on clinical outcomes?
Knowledge Generated
Molecular tumor boards reporting clinical outcomes had consistent structure and function. They are usually interdisciplinary,
function as a consult service, and appear to improve clinical outcomes, including response and progression-free survival;
however, studies are heterogeneous and data quality is limited.
Relevance
As the number of targetable mutations continues to increase and cancer care becomes even more complex, consultation with
an interdisciplinary molecular tumor board can help guide therapy selection for patients with cancer.
Molecular Tumor Boards: A Systematic Review
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review, and four more were added after a screen of bibli-
ographies and other additional resources. Fourteen total
articles were reviewed for this systematic analysis (Fig 1).
Study Characteristics
For inclusion in this systematic review, the studies had to
report CB, response rate, or survival among patients re-
ceiving MTB-recommended therapies. All studies were
observational, and the majority were retrospective. About
half of the studies screened fewer than 100 patients with a
range of 34-2,579 for all studies. The majority of studies
used large (more than 300 genes) commercial or in-house
panels, with two using in-house whole-exome sequencing
and one using a small (37 gene) panel. All studies took
place in the United States,13-22 France,23-25 or the
Netherlands26 with the majority being single institution
studies at academic medical centers. Eleven of the articles
outlined MTBs that had reviewed patient cases for more
than 1 year with only one reviewing for less than 1 year and
two not reporting duration of review.
The authors for all publications analyzed similar aims for
each of their tumor boards with one or all of the following
stated:
1. To investigate the rate of mutations and examine their
clinical utility,
2. To breakdown complex genomic reports and guide
treatment,
3. To increase access to up-to-date precision medicine
treatment options and clinical trials, and
4. To determine the efficacy of a precision medicine
program.
The MTBs generally employed a consistent structure and
operations, composed of an interdisciplinary team of cli-
nicians and scientists, and operated essentially as a consult
service, making recommendations to the treating physician
rather than managing patients. Inclusion of a genetics
counselor was common, but not universal. In most cases,
treating physicians ordered NGS testing and then referred
patients to the MTB for evaluation. In one study, the MTB
was responsible for approving NGS, and in another study,
all patients were enrolled in a prospective sequencing study
with only a fraction of cases reviewed by the MTB (Tables 1
and 2). All MTBs, with one exception, made recommen-
dations on the basis of pathogenic or likely pathogenic
mutations, but one also included variants of unknown
significance (Appendix Table A1).
Characteristics of the Patient Populations
Most of the MTBs described reviewed cases for multiple
solid tumors with the exceptions of Kaderbhai et al23 and
Koopman et al26 (non–small-cell lung cancer only), Parker
et al17 (breast cancer only), and Rodriguez-Rodriguez
et al20 (gynecologic malignancies only). The mean and
median patient age for all studies (with the exception of Tafe
et al,21 which did not report age for their patients) was in the
range of 50-68 years. The study population and/or eligibility
requirements for MTB review were similar across all
studies. The majority of patients had advanced-stage
Articles retrieved from
database
(N = 71) 
Articles selected for
title and abstract review
(n = 32) 
Articles selected for full
text review
(n = 10)
Articles included in the
final analysis
(n = 14)  
Additional records found
through other sources








No clinical benefit reported
(n = 22)
FIG 1. Study schema.
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TABLE 1. Clinical Outcome of MTBs—Cross-Sectional Cohort Studies





















Treatment Outcomes If ITT









53 (1.5-86) NR 165 141 of 165
(85%)
92 of 141 (65%) 31 of 92 (34%) CB: 13 of 31
(42%)
CB: 13 of 165
(8%)







Solid 57 (33-88) 2 (0-5) 38 38 of 38 (100%) 32 of 38 (84%) 9 of 32 (28%) CB: 4 of 9 (44%)
ORR: 2 of 9 (22%)
CB: 4 of 38
(11%)
ORR: 2 of 38
(5%)










NR 191 132 of 192
(69%)
48 of 132 (36%) 15 of 48 (31%) CB: 8 of 15 (53%)
ORR: 3 of 15
(20%)
CB: 8 of 191
(4%)
ORR: 3 of 191
(2%)





In-house panel NSCLC 61 (42-78) 2.3a (1-7) 50 48 of 50 (96%) 29 of 48 (60%) 9 of 29 (31%) CB: 7 of 9 (78%)b
ORR: 4 of 9 (44%)
CB: 7 of 50
(14%)
ORR: 4 of 50
(8%)




In-house panel NSCLC 68 (36-89) NR
68% with 0
32% with ≥ 1
129 110 of 129
(85%)
76 of 110 (69%) 25 of 76 (33%) CB: 17 of 21c
(81%)
ORR: 14 of 21
(67%)
CB: 17 of 129
(13%)









Commercial panels Gynecologic 61 (22-80) NR but only rare or
refractory
included
69 68 of 69 (99%) 64 of 68 (94%) 25 of 64 (39%) CB: 16 of 25
(64%)
ORR: 10 of 25
(40%)
CB: 16 of 69
(23%)








Commercial panels Solid 56 (29-75) 3a (1-13) 34 34 of 34 (100%) 33 of 34 (97%) 12 of 33 (36%) CB: 7 of 12 (58%)
ORR: 3 of 12
(25%)
CB: 7 of 34
(21%)
ORR: 3 of 34
(9%)




In-house panel Solid NR 2a (1-7) 35 35 of 35 (100%) 18 of 35 (51%) 2 of 18 (11%) CB: 2 of 2 (100%)
ORR: 1 of 2 (50%)
CB: 2 of 35
(6%)
ORR: 1 of 35
(3%)








58 (44-63) NR but only
advanced
disease




163 of 1,032 (15%) CB: 80 of 182d
(43%)











Commercial panels Solid 64 (37-82) 2.4 (1-6) 54 54 of 54 (100%) 54 (100%) 12 of 54 (22%) CB: 9 of 12 (75%)
ORR: 0 of 12 (0%)
CB: 9 of 54
(17%)
ORR: 0 of 54
Abbreviations: CB, clinical benefit; ITT, intention to treat; MTB, molecular tumor board; NR, not reported; NSCLC, non–small-cell lung cancer; ORR, overall response rate.
aMedian.
bProgression-free survival of 3 months considered stable disease.
cOutcomes of four individuals on clinical trials NR.
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TABLE 2. Clinical Outcome of MTBs—Before-After Studies
































Commercial panels Solid 59 (17-73) 2 (0-10) 155 155 of 155
(100%)










CI, 26 to 71
Conv.: 20%, 95%








Commercial panels Breast 59 (range
NR)
3a (1-13) 43 43 of 43
(100%)
40 of 43 (93%) 17 of 40 (43%) CB: 7 of 17 (41%)
ORR: 5 of 17 (29%)
PFS ratio ≥ 1.3 in 7
of 17 (41%)
CB: 7 of 43
(16%)








Commercial panels Solid 55 (range
NR)
4a (2-6) 168 168 of 168
(100%)
NR 44 of NR PFS ratio ≥ 1.3
MTB: 19 of 44
(43%)






HR = 0.55 (95%











Solid 65 (24-94) 2a (1-8) 506 386 of 506
(76%)
342 of 506 (68%)
(included VUS)
79 of 342 (23%) PFS ratio ≥ 1.3
MTB: 12 of 48
(25%)
Conv.: 23 of 89
(26%)
NS
P = .8 (χ2 test)
NA
Abbreviations: CB, clinical benefit; conv., conventional; HR, hazard ratio; ITT, intention to treat; MTB, molecular tumor board; NA, not applicable; NR, not reported; NS, not significant; ORR, overall
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disease and had received several prior therapies with most
having exhausted all SOC options.
Quality Assessment
Study quality was analyzed using the quality assessment
tools provided by the National Institutes of Health.11 If the
main outcomes of a study included comparing survival on
an MTB-directed treatment with patients’ prior treatment,
the study was classified as before-after, and quality was
assessed with Quality Assessment Tool for Before-After
(Pre-Post) Studies with No Control Group (Table 3). All
other studies were classified as cross-sectional cohort
studies, and quality was assessed with Quality Assessment
Tool for Observational Cohort and Cross-Sectional Studies
(Table 4). Most groups reported similar eligibility require-
ments or described their patient populations, and almost all
patients were followed until progression on MTB therapy,
and therefore used an appropriate timeframe to measure
patient outcomes. Physician or patient choice, insurance,
geographic location of clinical trials, and waiting to exhaust
SOC options were the main reasons for not accepting MTB
recommendations.
Bias analysis was performed using the tool from the
Cochrane Institute.12 Nine of the 14 studies did not include
a matched control, neither a cohort of untreated patients
nor by comparing MTB-recommended therapies with the
patients’ prior therapy. This resulted in those studies re-
ceiving the lowest score in that category, but the overall
level of bias was low (Table 5).
Genetic Testing and Actionable Mutations
The types of sequencing varied among studies and within
studies. The majority of samples were sent to commercial
Clinical Laboratory Improvement Amendments laboratories
with the most common being FoundationOne. Some re-
searchers used on-site clinical laboratories to perform all
DNA extraction and sequencing. The types of testing used
included whole-exome sequencing, gene panels, and
comparative genomic hybridization. Each study defined an
actionable mutation differently with four18-20,22 of the 14
studies not defining actionability at all. Those studies that
used on-site clinical laboratories also varied in their deci-
sion making in regard to somatic calls, using different
databases, and publications, to determine each patient’s
mutation profile. We calculated actionability rates for each
study that provided sufficient data as described inmethods.
The frequency of actionable mutations ranged from 36% to
100%. Of note, the only MTB that considered tumor mu-
tation burden an actionable mutation was the most recently
published.24 We diagrammed these actionability rates
along each study timeline in Appendix Figure A1 (for those
studies that included the timeframe of data collection). In
general, rates of actionability increased over time, likely
because of new targets and drug approvals. Exceptions
were Koopman et al,26 who only evaluated lung cancer,
where the most common targetable driver mutations have
been known for decades, and Parker et al17 and Rodriguez-
Rodriguez et al,20 who focused on breast and gynecological
malignancies, respectively, where new targetable have
been slow to be identified.
Clinical Outcomes
To assess clinical outcomes, studies were divided into
before-after or cross-sectional cohort studies. For the cross-
sectional cohort studies, the percentage of patients re-
ceiving MTB-recommended targeted therapies ranged
from 11% to 39%. Although reasons for not receiving an
MTB-directed therapy were not frequently reported, when
reported, the most common reasons were lack of action-
able mutations, rapidly progressive disease, and when
clinical trials were recommended by the MTB, patients
were unwilling to travel or ineligible.14 The frequency of
patients achieving a CB from MTB-directed therapies
ranged from 42%14 to 100%,21 although one study21
TABLE 3. Quality Assessment of Before-After Studies
Quality Criteria Dalton et al15 Parker et al17 Radovich et al19 Réda et al24
Clearly stated question or objective No No Yes No
Study eligibility clearly described Yes No Yes Yes
Participants’ representative Yes Yes Yes Yes
All eligible patients enrolled Yes NR NR NR
Sample size sufficient No No Yes No
Intervention clearly described Yes Yes Yes Yes
Outcomes clearly defined, valid, reliable, and assessed consistently No No Yes No
Outcome assessors blinded No No No No
Loss to follow-up ≤ 20% Yes Yes NR Yes
Statistical methods provide P for pre- to postchanges No Yes Yes No
Outcome measures taken multiple times before and after intervention NA NA NA NA
Statistical analysis for group to individual effect NA NA NA NA
Abbreviations: NA, not applicable; NR, not reported.
Molecular Tumor Boards: A Systematic Review
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reported clinical outcomes for only two patients. Kaderbhai
et al23 and Koopman et al26 reported excellent CB rates of
78% and 81%, respectively, in patients with non–small-cell
lung cancer. ORRs ranged from 0% to 67% reported by
Trivedi et al22 and Koopman et al,26 respectively, with none
of the patients in Trivedi’s study achieving a partial or CR.
For the before-after studies, the percentage of patients
receiving MTB-recommended targeted therapies ranged
from 22% to 43%. There were two prospective trials re-
ported, the first by Radovich et al19 who prospectively
compared the PFS ratio and PFS for 168 patients referred
to their MTB. Of these, 67 were lost to follow-up or had
insufficient follow-up duration and were excluded. Of the
remainder, 44 received a genomically targeted therapy and
57 received nontargeted therapy. Patients with an ac-
tionable mutation and receiving a targeted therapy had
improved PFS (mean 86 days) compared with those not
receiving genomic therapy (mean 49 days, hazard ratio:
0.55, 95% CI, 0.37 to 0.84). In addition, 43.2% of those
with a targeted therapy achieved a PFS ratio of ≥ 1.3,
compared with only 5.3% of those with nontargeted ther-
apy, P , .0001. Réda et al24 evaluated 506 patients who
were referred for NGS and were able to perform sequencing
on 386. The primary end point was feasibility of the
approach, defined as proportion of individuals who re-
ceived a recommendation on the basis of their genomic
report. Overall, 79 received a recommended therapy;
however, there was no difference proportion of patients
achieving a PFS of≥ 1.3 between genomically targeted and
standard therapy.
DISCUSSION
Somatic genomic sequencing has added additional layers
of complexity to diagnosing and treating cancer. Molecular
tumor boards have been developed to assist with assessing
and acting on genomic reports.6,27 All the studies analyzed
for this review stated similar aims for their molecular tumor
boards, using them as an opportunity to break down the
complexity of genomic testing and reporting, increase
access to up-to-date treatments and clinical trials, and
better understand the clinical utility of precisionmedicine in
oncology.
Nine of the 14 studies analyzed for this review had CB and/
or response rate as the primary outcome. None of these
studies were randomized nor were they controlled for
non–MTB-directed outcomes, thus making it difficult to
determine the effectiveness of molecular targeted therapies
and the recommendations of their MTBs. ORRs in these

























No No No No No No No No No No
Defined population Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Participation rate
of ≥ 50%




Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Sample size justification No No No No No No No No No No
Exposures measured
before the outcome
NA NA NA NA NA NA NA NA NA NA
Sufficient timeframe Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Different levels or
exposures examined
NA NA NA NA NA NA NA NA NA NA
Exposure measures
clearly defined
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Outcome measures
clearly defined
No No No No No No No No No No
Outcome assessors
blinded
No No No No No No No No No No
Loss to follow-
up ≤ 20%
Yes Yes Yes NR NR Yes NR NR NR Yes
Compounding variables
measured
No No No No No No No No No No
Abbreviations: NA, not applicable; NR, not reported.
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studies ranged from 0% to 67%, which favorably compared
with previously published ORRs of 5% in unmatched phase I
trials28 and 6% for all phase I trials in a single institution.29
Trédan et al22 not only had the largest patient cohort but also
used the smallest gene panel for their NGS testing, resulting
in a relatively low rate of patients with an actionablemutation.
Koopman et al26 reported a high CB in patients receiving an
off-label drug, but the authors indicated stricter criteria for
off-target therapies than other studies, denoting that mu-
tations in downstream pathways were not considered for off-
target therapies of an upstream protein.
The three studies that either used patients’ PFS ratio or
compared PFS between patient groups allowed for a more
direct analysis of the efficacy of the MTB-directed thera-
pies. Of these, one was positive,19 one trended toward
superiority,15 and one found no difference.24 Since PFS
typically decreases with every subsequent therapy, a minor
increase in PFS2 may be noteworthy in this population.30
Comparing outcomes across a wide variety of reports with
different primary outcomes, patient populations, and cri-
teria for recommendations makes definitive conclusions
difficult; however, generally, positive benefits were seen.
Outcomes reported in trials without a control arm did ap-
pear to bemuch better than in other salvage situations such
as phase I trial responses from the era before targeted
therapy.29,30 Among those trials with a control arm, while
not conclusive, MTBs provide CB and at least do no harm.
In addition, overall impressions from the authors of each
study were positive in regard to the utility of the MTBs at
their respective institutions and suggested that each MTB
helped to inform treatment decisions and increase access
to genetic counseling for patients.
Although clinical trials comparing targeted therapies with
standard therapies in those with a biomarker are almost
universally positive, the reported benefit of NGS for the
selection of therapy has been mixed. Several NCI-MATCH
study arms demonstrate promising results. In arm H, pa-
tients with BRAFV600 mutations were treated with dab-
rafenib and trametinib. This arm met its primary end point,
with an ORR of 33%.31 The MOSCATO trial concluded that
NGS improved outcomes, but only among a small subset of
patients with targetable mutations.32 The SHIVA trial was a
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NA NA NA NA NA NA NA NA NA NA NA NA NA NA
NOTE. 1, definitely yes; 2, probably yes; 3, probably no; 4, definitely no.
Abbreviation: NA, not applicable.
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randomized phase II trial that included patients with a
mutation in one of the three pathways, hormone receptors,
PI3K, or RAF, and matched them to one of the 11 different
targeted therapies. In this trial, there was no improvement
in survival after treatment with targeted therapies.33 The
SHIVA trial has been criticized for its design, for both
assigning therapies with unproven activity for the targets
and using an algorithm that only considered mutations in
the targeted arm, whereas physician discretion was allowed
in the control arm. The number of patients eligible for
targeted therapies increased between 2006 and 2018,
likely because of more targeted therapy approvals every
year, but that fewer than 7% actually benefitted, whereas
only 16% were eligible.34
Advances in NGS technologies are also identifying addi-
tional patients with actionable mutations. High tumor
mutation burden, an indication for pembrolizumab in any
tumor type,31 loss of heterozygosity, an indication for poly
(ADP-ribose) polymerase inhibition for prostate cancer,32
and certain RNA fusions, which confer sensitivity to specific
targeted therapies, are now routinely reported on many
NGS panels.33 In addition, there is an increasing awareness
of the ability of somatic mutation testing to identify potential
germline mutations.35 In addition to being targetable with
small molecules, these germline mutations are clinically
important to the patient’s family members and support the
need for inclusion of genetic counselors in the MTB team.
As the number of eligible patients continues to rise, it will
become increasingly important for clinicians to accurately
interpret complex genomic test results and to have in-
creased access to therapies and clinical trials. Resources
such as interprofessional MTBs can help clinicians navi-
gate the complex world of precision medicine and provide
these advanced treatments to their patients. Furthermore,
as larger cohorts of data become available and shared,
standardizing the components of an MTB, such as the
definition of actionability, use of off-target drugs, and the
types of sequencing will be imperative.
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FIG A1. Actionability rates by year.
TABLE A1. Definitions of Actionability as Provided by the Authors
Reference Definition of Actionability
Bryce et al13 An aberration with known functional significance that could be
therapeutically targeted with an FDA-approved drug or clinical trial
Burkard et al14 Allowed for identification of a molecular-targeted clinical trial or off-trial
treatment
Dalton et al15 Offered a target for a drug approved by the FDA, an FDA-approved drug
off-label, a clinical trial, or was a potential germline mutation for a
hereditary syndrome
Harada et al16 Variants classified as predictive or prognostic of any tumor types or have
been reported in cancer and had available clinical trials
Kaderbhai et al23 Associated with FDA-approved drugs, potentially targetable when
associated with a clinical trial or potential sensitivity to a drug
Koopman et al26 Tier 1 or 2 according to 2017 American College of Medical Genetics
guidelines or existence of effective targeted therapy options
Parker et al17 An FDA-approved drug or in clinical trials that targeted at low nanomolar
concentrations or was the primary target of an antibody
Radovich et al19 NR
Réda et al24 Class I-III variants with some class IV according to European Society of
Medical Oncology Scale for Clinical Actionability of Molecular Tests
guidelines, included some VUS
Rodriguez-Rodriguez et al20 NR
Schwaederle et al18 NR
Tafe et al21 Associated with available (approved, off-label, or experimental) targeting
of the affected pathway
Trédan et al25 NR
Trivedi et al22 Linked as either a positive or negative biomarker for an approved therapy
or enrollment criteria for an open clinical trial
Abbreviations: FDA, US Food and Drug Administration; NR, not reported; VUS, variants of unknown significance.
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